Stock Events

Stock Events

Vericel 

$54.62
32
+$2.84+5.48%Friday 20:59
+$1.70+3.11%Saturday 00:30After hours

Statistics

Day High
54.64
Day Low
54.49
52W High
55.6
52W Low
28.95
Volume
31,184
Avg. Volume
-
Mkt Cap
2.8B
P/E Ratio
109.3
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.23
-0.03
0.18
0.38
Expected EPS
0.05725
Actual EPS
N/A

Financials

5.98%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
276.26MRevenue
16.52MNet Income

Analyst Ratings

$63.67Average Price Target
The highest estimate is ⁦75.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VCEL. It's not an investment recommendation.
NVIDIA
11
NVDA
Microsoft
10
MSFT
Amazon
10
AMZN
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mimedx Group
MDXG
Mkt Cap566.19M
MiMedx Group, Inc. specializes in regenerative biomaterials similar to Vericel's focus on autologous cell therapies, making them direct competitors in the regenerative medicine space.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics Inc. is involved in developing autologous stem cell therapies for debilitating neurological diseases, a field related to Vericel's therapeutic areas.
Mesoblast
MESO
Mkt Cap1.97B
Mesoblast Limited focuses on regenerative medicine and cell therapy, making it a competitor in the same innovative medical field as Vericel.
Fate Therapeutics
FATE
Mkt Cap249.23M
Fate Therapeutics, Inc. is engaged in the development of programmed cellular immunotherapies, competing with Vericel in the broader cell therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics AG operates in the gene editing and cell therapy space, presenting a futuristic alternative to Vericel's current cell therapy solutions.

About

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Show More
CEO
Dominick C. Colangelo
Employees
398
Country
United States
ISIN
US92346J1088
WKN
000A12FU4

Listings

STU
DE
ATQP.STU
MU
DE
ATQP.MU
BOATS
BOATS
VCEL.BOATS
F
DE
ATQP.F

0 Comments

Share your thoughts

FAQs

What is Vericel stock price today?▼
The current price of VCEL is $54.62 USD — it has increased by +5.48% in the past 24 hours. Watch Vericel stock price performance more closely on the chart.
What is Vericel stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vericel stocks are traded under the ticker VCEL.
Is Vericel stock price growing?▼
VCEL stock has risen by +35.67% compared to the previous week, the month change is a +36.38% rise, over the last year Vericel has showed a +40.27% increase.
What is Vericel market cap?▼
Today Vericel has the market capitalization of 2.8B
When is the next Vericel earnings date?▼
Vericel is going to release the next earnings report on February 25, 2027.
What is Vericel revenue for the last year?▼
Vericel revenue for the last year amounts to 276.26M USD.
What is Vericel net income for the last year?▼
VCEL net income for the last year is 16.52M USD.
How many employees does Vericel have?▼
As of November 8, 2026, the company has 398 employees.
In which sector is Vericel located?▼
Vericel operates in the Health & Wellness sector.
When did Vericel complete a stock split?▼
The last stock split for Vericel was on October 16, 2013 with a ratio of 1:20.
Where is Vericel headquartered?▼
Vericel is headquartered in BURLINGTON, United States.